{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:05:23Z","timestamp":1784019923190,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Caspofungin, micafungin, and anidulafungin are three commonly used echinocandins recommended for the treatment of invasive candidiasis. This study aimed to comprehensively evaluate the safety profiles of these three agents to assist clinicians in making appropriate therapeutic decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) database was performed. Adverse event (AE) reports were collected from January 2004 to March 2025. The reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network were used to identify, assess, and compare AE signals of the three echinocandins. Data from the VigiAccess database were used for external validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2343, 2338, and 406 cases associated with caspofungin, micafungin, and anidulafungin, respectively, were extracted from the FAERS database. Caspofungin exhibited a tendency toward higher reporting frequencies of hepatobiliary disorders and skin and subcutaneous tissue disorders compared with micafungin and anidulafungin. Hepatobiliary signals observed for anidulafungin should be interpreted cautiously, as they may reflect confounding by indication related to preferential use in patients with underlying hepatic dysfunction rather than direct drug toxicity. A range of AEs that were not highlighted in the labels were identified. Logistic regression analyses indicated that skin and subcutaneous tissue disorders associated with caspofungin or micafungin were significantly associated with hospitalization reporting. Supplementary PT-level analyses further identified several clinically relevant AEs associated with hospitalization, including drug reaction with eosinophilia and systemic symptoms for caspofungin, renal failure for micafungin, and hepatic failure for anidulafungin. Higher disproportionality signals related to caspofungin and micafungin were observed in patients aged\u226565 years and females. Additionally, the sensitivity analyses demonstrated that this study possessed good robustness. The median time-to-onset of AEs was significantly longer for caspofungin at 4 days (IQR: 0\u201311\u00a0days) than for micafungin at 2\u00a0days (IQR: 0\u20138\u00a0days,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and anidulafungin at 1\u00a0day (IQR: 0\u201310 days,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001). The results in VigiAccess were broadly consistent with FAERS findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a comparative pharmacovigilance overview of the safety profiles of three echinocandins using FAERS and VigiAccess data. Further prospective studies are needed to validate these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1840717","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:48:45Z","timestamp":1781768925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingxiu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Department of Clinical Pharmacy Translational Science, University of Michigan College of Pharmacy","place":["Ann Arbor, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]},{"name":"Department of Pharmacy, Guangxi Hospital Division of the First Affiliated Hospital, Sun Yat-sen University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.70389\/pjs.100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of artificial intelligence","author":"Agha","year":"2025","journal-title":"Premier J. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00101-014-2289-8","article-title":"Effects of echinocandin preparations on adult rat ventricular cardiomyocytes. Preliminary results of an in vitro study","volume":"63","author":"Arens","year":"2014","journal-title":"Anaesthesist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/21505594.2016.1257457","article-title":"New facets of antifungal therapy","volume":"8","author":"Chang","year":"2017","journal-title":"Virulence"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","article-title":"Echinocandin antifungal drugs in fungal infections: a comparison","volume":"71","author":"Chen","year":"2011","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12959-024-00641-4","article-title":"Coagulation dysfunction events associated with echinocandins: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"22","author":"Cheng","year":"2024","journal-title":"Thromb. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12877-021-02512-3","article-title":"Risk of antimicrobial-associated organ injury among the older adults: a systematic review and meta-analysis","volume":"21","author":"Chinzowu","year":"2021","journal-title":"BMC Geriatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S662","DOI":"10.1093\/cid\/civ739","article-title":"Antifungal-associated drug-induced cardiac disease","volume":"61","author":"Cleary","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1111\/jdv.17808","article-title":"Calcinosis cutis in epidermal necrolysis: role of caspofungin?","volume":"36","author":"Colboc","year":"2022","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the national pharmacovigilance centre in the Netherlands: an explorative observational study","volume":"85","author":"de Vries","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/jid.2011.256","article-title":"Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis","volume":"132","author":"Denda","year":"2012","journal-title":"J. Invest. Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1007\/s00253-013-4761-9","article-title":"Echinocandins: production and applications","volume":"97","author":"Emri","year":"2013","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jcpt.12046","article-title":"A severe case of haemodynamic instability during anidulafungin administration","volume":"38","author":"Fink","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1310286","DOI":"10.3389\/fphar.2024.1310286","article-title":"A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases","volume":"15","author":"He","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13293-021-00377-0","article-title":"Sex differences associated with adverse drug reactions resulting in hospital admissions","volume":"12","author":"Hendriksen","year":"2021","journal-title":"Biol. Sex Differ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bcpt.13679","article-title":"Clinical predictors of nephrotoxicity associated with teicoplanin: meta-Analysis and meta-regression","volume":"130","author":"Hirai","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1481114","DOI":"10.3389\/fphar.2025.1481114","article-title":"Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1016\/S1473-3099(24)00102-6","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Ikuta","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.idc.2021.03.005","article-title":"Antifungals in clinical use and the pipeline","volume":"35","author":"Johnson","year":"2021","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1055\/s-2008-1063859","article-title":"Update on echinocandin antifungals","volume":"29","author":"Kauffman","year":"2008","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1128\/AAC.04446-14","article-title":"Cardiac effects of echinocandins after central venous administration in adult rats","volume":"59","author":"Koch","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1128\/AAC.01766-15","article-title":"Cardiac effects of echinocandins in endotoxemic rats","volume":"60","author":"Koch","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e01114","DOI":"10.1128\/AAC.01114-18","article-title":"Caspofungin modulates ryanodine receptor-mediated calcium release in human cardiac myocytes","volume":"62","author":"Koch","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/2047-783x-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1632488","DOI":"10.3389\/fphar.2025.1632488","article-title":"Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41746-025-02173-1","article-title":"Computational pharmacovigilance of lifitegrast in dry eye disease using machine learning and network toxicology","volume":"9","author":"Li","year":"2026","journal-title":"NPJ Digit. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jcpt.12078","article-title":"Cardiac effects of echinocandin preparations - three case reports","volume":"38","author":"Lichtenstern","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S2468-1253(20)30006-6","article-title":"Drug-induced liver injury in older people","volume":"5","author":"Lucena","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/j.1365-2125.1998.00817.x","article-title":"Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies","volume":"46","author":"Martin","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clnu.2025.06.011","article-title":"Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: a vigibase study","volume":"51","author":"Nishida","year":"2025","journal-title":"Clin. Nutr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","article-title":"Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events","volume":"25","author":"Noren","year":"2006","journal-title":"Stat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/s0966-842x(03)00117-3","article-title":"Antifungal agents: mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Pan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1413944","DOI":"10.3389\/fphar.2024.1413944","article-title":"Safety profiles of doxycycline, minocycline, and tigecycline in pediatric patients: a real-world pharmacovigilance analysis based on the FAERS database","volume":"15","author":"Qiao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2010.08.038","article-title":"Calcinosis cutis: part I. Diagnostic pathway","volume":"65","author":"Reiter","year":"2011","journal-title":"J. Am. Acad. Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40266-023-01019-3","article-title":"Safety and tolerability of antimicrobial agents in the older patient","volume":"40","author":"Soraci","year":"2023","journal-title":"Drugs Aging"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/14740338.2013.829036","article-title":"Cardiac toxicity of some echinocandin antifungals","volume":"13","author":"Stover","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcpt.12108","article-title":"Cardiac toxicity of the echinocandins: chance or cause and effect association?","volume":"39","author":"Stover","year":"","journal-title":"J. Clin. Pharm. Ther."},{"key":"B45","unstructured":"Anidulafungin label\n          \n          \n          2020"},{"key":"B46","unstructured":"Caspofungin label"},{"key":"B47","unstructured":"Micafungin label"},{"key":"B48","unstructured":"Rezafungin label\n          \n          \n          2023"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","article-title":"Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy","volume":"70","author":"van De Ven","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"van Puijenbroek","year":"2003","journal-title":"Drug Saf."},{"key":"B52","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12879-018-3333-0","article-title":"Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication","volume":"18","author":"Vekeman","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1413709","DOI":"10.3389\/fphar.2024.1413709","article-title":"Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1002\/imt2.184","article-title":"Visualizing set relationships: evEVenn's comprehensive approach to venn diagrams","volume":"3","author":"Yang","year":"2024","journal-title":"Imeta"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"updated-by":[{"DOI":"10.3389\/fphar.2026.1916009","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1840717\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:20:40Z","timestamp":1784017240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1840717\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":57,"alternative-id":["10.3389\/fphar.2026.1840717"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1840717","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1840717"}}